BTK and B-cell chronic lymphocytic leukemia: On 14th November 2019 the FDA granted accelerated approval to the second generation oral BTK inhibitor zanubrutinib for the treatment of mantle cell lymphoma, with several ongoing or concluded clinical studies for the treatment of CLL [93,94,95,96,97].